Patents by Inventor Tomoyo TAKEO

Tomoyo TAKEO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IGF-I RECEPTOR HUMANIZED ANTIBODY
    Publication number: 20220033485
    Abstract: Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Teijin Pharma Limited
    Inventors: Akira TANOKURA, Hirotsugu KATO, Hiroshi EGUCHI, Kenichiro TAKAGI, Satoshi YAMAMURA, Naoko NAMIKI, Daisuke ISHIKAWA, Hirofumi HIGUCHI, Tomoyo TAKEO, Masayo OHORI
  • Anti-transthyretin human antibody
    Patent number: 11186630
    Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 30, 2021
    Assignee: KM BIOLOGICS CO., LTD.
    Inventors: Masaharu Torikai, Akihiko Hosoi, Tomoyo Takeo, Masayo Ueno, Kenji Soejima, Toshihiro Nakashima, Yukio Ando, Hirofumi Jono, Yu Su, Mineyuki Mizuguchi
  • ANTI-TRANSTHYRETIN HUMAN ANTIBODY
    Publication number: 20200181250
    Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 11, 2020
    Applicant: KM Biologics Co., Ltd.
    Inventors: Masaharu TORIKAI, Akihiko HOSOI, Tomoyo TAKEO, Masayo UENO, Kenji SOEJIMA, Toshihiro NAKASHIMA, Yukio ANDO, Hirofumi JONO, Yu SU, Mineyuki MIZUGUCHI
  • Anti-transthyretin humanized antibody
    Patent number: 10604562
    Abstract: A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The humanized antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a humanized antibody suitable for application to human body.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 31, 2020
    Assignees: KM BIOLOGICS CO., LTD., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Akihiko Hosoi, Masaharu Torikai, Tomoyo Takeo, Masayo Ueno, Hirofumi Higuchi, Kenji Soejima, Toshihiro Nakashima, Yukio Ando, Hirofumi Jono, Yu Su
  • Anti-transthyretin human antibody
    Patent number: 10597440
    Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 24, 2020
    Assignee: KM BIOLOGICS CO., LTD.
    Inventors: Masaharu Torikai, Akihiko Hosoi, Tomoyo Takeo, Masayo Ueno, Kenji Soejima, Toshihiro Nakashima, Yukio Ando, Hirofumi Jono, Yu Su, Mineyuki Mizuguchi
  • ANTI-TRANSTHYRETIN HUMANIZED ANTIBODY
    Publication number: 20160347832
    Abstract: A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The humanized antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a humanized antibody suitable for application to human body.
    Type: Application
    Filed: January 23, 2015
    Publication date: December 1, 2016
    Applicants: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSIT Y
    Inventors: Akihiko HOSOI, Masaharu TORIKAI, Tomoyo TAKEO, Masayo UENO, Hirofumi HIGUCHI, Kenji SOEJIMA, Toshihiro NAKASHIMA, Yukio ANDO, Hirofumi JONO, Yu SU
  • ANTI-TRANSTHYRETIN HUMAN ANTIBODY
    Publication number: 20160340419
    Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 24, 2016
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Masaharu TORIKAI, Akihiko HOSOI, Tomoyo TAKEO, Masayo UENO, Kenji SOEJIMA, Toshihiro NAKASHIMA, Yukio ANDO, Hirofumi JONO, Yu SU, Mineyuki MIZUGUCHI